Welcome to our dedicated page for Privia Health Group SEC filings (Ticker: PRVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
Privia Health Group Chief Executive Officer Parth Mehrotra reported a mix of stock awards and a planned share sale. He received 171,904 shares of common stock as a grant or award on March 11, 2026, and 141,342 shares as a grant or award on March 10, 2026, both at no cash cost to him.
On March 10, 2026, he sold 21,097 shares of common stock at a weighted average price of $22.71 per share, with individual trade prices ranging from $22.27 to $23.23, under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 635,944 shares of Privia Health Group common stock.
Fargis Edward C reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group, Inc. executive vice president and general counsel Edward C. Fargis reported receiving a grant of 28,268 shares of common stock in the form of restricted stock units at no cash cost per share. These units were awarded under the 2021 Omnibus Incentive Plan.
The restricted stock units will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally contingent on continued service through each vesting date. Following this grant, Fargis directly holds 111,979 shares of common stock.
Mountcastle David reported acquisition or exercise transactions in this Form 4 filing.
Privia Health Group EVP & CFO David Mountcastle reported equity awards of common stock. He received 42,584 shares and 35,335 shares of common stock at a price of $0.00 per share as compensation grants, increasing his direct holdings to 239,822 shares.
Footnotes explain these shares relate to restricted stock units under the 2021 Omnibus Incentive Plan that vest in three equal annual installments and to performance stock units granted on May 9, 2023 for the 2023–2025 performance period that have now vested and been distributed. An additional 8,695 shares are held indirectly by his spouse.
Parth Mehrotra reported sales of Common Stock under Rule 144. The filing lists sales of 21,440 shares on 03/06/2026, 41,999 shares on 03/09/2026 and 21,097 shares on 03/10/2026. The excerpt also shows a Restricted Stock Vesting entry for 26,763 shares on 03/11/2026.
PRVA filed a Form 144 to sell 6,453 shares of Common Stock. The filing lists the proposed sale as resulting from restricted stock vesting tied to compensation with a transaction date of 03/11/2026 and names Fidelity Brokerage Services LLC as the broker. The filing also lists multiple sales by David Mountcastle during the prior three months: 23,887 shares on 12/12/2025, 5,361 shares on 02/26/2026, 7,697 shares on 02/27/2026, 5,177 shares on 03/06/2026, and 5,829 shares on 03/09/2026, with dollar proceeds listed alongside each sale.
PRVA submitted a Form 144 reporting a proposed sale of 21,097 shares of Common Stock. The filing lists the broker Fidelity Brokerage Services LLC and dates around 03/08/2026–03/10/2026.
The filing also discloses recent sales by Parth Mehrotra: 21,440 shares on 03/06/2026 for $496,357.44 and 41,999 shares on 03/09/2026 for $960,197.55.
Privia Health Group CEO Parth Mehrotra reported open-market sales of 63,439 common shares of Privia Health Group, Inc. on March 6 and 9, 2026 at weighted-average prices including 22.84, 23.15 and 23.37 per share. The filing explains these were nondiscretionary “sell-to-cover” trades required to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and were executed under a Rule 10b5-1 trading plan. After these transactions, Mehrotra directly holds 343,795 shares of Privia common stock.
Privia Health Group EVP & General Counsel Edward C. Fargis reported two stock sales that were required to cover taxes on vested restricted stock units. On March 6, 2026, he sold 4,394 shares at $23.15 per share, followed by 4,949 shares at $22.84 per share on March 9, 2026. The footnote explains these were nondiscretionary “sell to cover” transactions to satisfy tax withholding obligations, rather than elective open-market sales. After the transactions, he directly owned 83,711 shares of Privia Health Group common stock.
Privia Health Group, Inc. Executive Vice President and Chief Financial Officer David Mountcastle reported open-market sales totaling 11,006 shares of common stock on March 6 and March 9, at prices of $23.15 and $22.84 per share.
According to the filing, these were nondiscretionary sell-to-cover transactions required to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units. After the transactions, he directly holds 161,903 shares and indirectly holds 8,695 shares through his spouse.
Parth Mehrotra reported a sale of common stock. The filing shows a sale of 21,440 common shares on 03/06/2026 for $496,357.44 under Form 144. The filing also records the vesting of 23,134 restricted shares on 03/05/2026 as compensation.